Issue |
E3S Web of Conf.
Volume 553, 2024
2024 International Conference on Ecological Protection and Environmental Chemistry (EPEC 2024)
|
|
---|---|---|
Article Number | 05009 | |
Number of page(s) | 6 | |
Section | Medical Treatments and Therapies | |
DOI | https://doi.org/10.1051/e3sconf/202455305009 | |
Published online | 24 July 2024 |
Advancements in Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma
School of Medicine, Shanghai Jiao Tong University, Shanghai, China
* Corresponding author: email: 1911441109@mail.sit.edu.cn
Chimeric antigen receptor T cell (CAR-T) therapy nowadays symbolizes an innovative paradigm of neoplasm immunotherapy that employs genetic engineering techniques to empower T cells and make it have a capability to precisely identify tumor-associated antigens, thereby unleashing potent anti-tumor responses. The remarkable success observed in leukemia and lymphoma treatment has shown the possibility for extending CAR-T therapy’s potential to solid tumors. In the context of hepatocellular carcinoma (HCC), the prevailing form of primary hepatic malignancy, diagnosis frequently occurs during advanced stages, imposing significant challenges. The current options available for managing HCC are notably limited, and though previous research has showcased the feasibility of CAR-T cell application, achieving optimal therapeutic outcomes has remained elusive. This phenomenon can be induced by various factors including adverse effects , tumor microenvironment, the diversity inherent in tumor antigens, heightened intratumor pressures and the immunosuppressive context within exhaustion of CAR-T Cells. All of these reasons undermine the effectiveness of this therapy and a multitude of ongoing clinical investigations and preclinical research are underway to overcome these hurdles. This comprehensive review concisely outlines the function of this therapy, existing targets of HCC treatment and examines the current impediments and offers potential resolutions within the context of HCC.
© The Authors, published by EDP Sciences, 2024
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.